Pulmonx Corporation Achieves $5.38 Consensus Price Target from Analysts

Pulmonx Corporation (NASDAQ:LUNG) has received an average price target of $5.38 from eight research firms that provide coverage on the company. According to MarketBeat Ratings, the consensus rating for the stock is “Hold,” with one analyst issuing a sell recommendation, three advising a hold, and four recommending a buy.

Recent research reports have highlighted various ratings for Pulmonx. On March 5, 2024, Canaccord Genuity Group lowered its target price for Pulmonx from $6.00 to $5.00 while maintaining a “buy” rating. In the same vein, D. Boral Capital reaffirmed a “buy” rating but set a significantly higher target price of $14.00. Weiss Ratings also reissued a “sell (e+)” rating on Pulmonx on January 22, 2024, while Wall Street Zen upgraded the stock from a “sell” to a “hold” rating on November 16, 2023.

Institutional investors have shown considerable interest in Pulmonx, purchasing and selling shares throughout recent quarters. For instance, ExodusPoint Capital Management LP acquired a new stake valued at approximately $4.31 million during the fourth quarter of 2023. Additionally, Vestal Point Capital LP invested about $1.35 million in the third quarter. State Street Corp increased its holdings by 3.6% in the fourth quarter, bringing its total to 821,217 shares valued at around $1.82 million. Notably, Bank of America Corp DE elevated its position by an astonishing 556.6%, owning 481,268 shares valued at $1.25 million by the end of the previous quarter.

Recent Financial Performance and Market Data

Shares of Pulmonx opened at $1.68 on the most recent trading day. The company has a market capitalization of $70.96 million and a debt-to-equity ratio of 0.68. It reported a negative price-to-earnings (P/E) ratio of -1.26 and a beta of 0.07. The stock has fluctuated between a 52-week low of $1.31 and a high of $8.12.

In its most recent earnings report on March 4, 2024, Pulmonx reported a loss of ($0.25) per share, surpassing analysts’ expectations of ($0.39) by $0.14. The company’s revenue for the quarter was $22.60 million, exceeding the consensus estimate of $21.73 million. Despite this, the company has reported a negative return on equity of 82.79% and a negative net margin of 59.67%. Analysts anticipate Pulmonx will report earnings of ($1.55) per share for the current fiscal year.

About Pulmonx Corporation

Pulmonx Corporation is a commercial-stage medical device company dedicated to bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship product, the Zephyr® Endobronchial Valve System, utilizes one-way valves delivered through a minimally invasive bronchoscopic procedure to collapse diseased sections of the lung. This process reduces hyperinflation and enhances respiratory function.

Additionally, Pulmonx provides the Chartis® Pulmonary Assessment System, which offers clinicians essential quantitative measurements of collateral ventilation, thereby aiding in patient selection and optimizing clinical outcomes. The Zephyr Valve received its CE mark in Europe in 2008 and was granted FDA approval in the United States in 2018. It has since been adopted by leading respiratory and thoracic centers across North America and Europe.

As Pulmonx continues to navigate the evolving landscape, analysts and investors will be closely monitoring its performance and strategic decisions in the coming months.